fourier: use of pcsk9 inhibitor evolocumab - acc.17
Published 7 years ago • 3.3K plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
3:39
fourier
-
3:26
achieving very low ldl-c levels with the pcsk9 inhibitor evolocumab
-
1:05:30
pcsk9 inhibition: lowering lipids and reducing cardiovascular events
-
6:49
looking to fourier what do the trials tell us about ldl lowering and cardiovascular events
-
5:46
pcsk9 inhibition in subjects with elevated risk
-
11:39
will pcsk9 inhibitors render pci obsolete? - gregory schwartz, md
-
7:51
efficacy and safety of pcsk9 inhibitors
-
3:34
how will fourier impact clinical practice, including treatment access?
-
3:09
pcsk9 inhibitors - video abstract id 83719
-
3:40
osler trials suggest pcsk9 inhibitor reduces cardiovascular events long term
-
2:36
fourier trial research overview
-
2:02
dr brian ference: does fourier align with results from the cttc meta-analysis?
-
2:29
amgen’s repatha cholesterol drug cuts risk of cardiovascular events in clinical trial
-
5:41
what is pcsk9 and how pcsk9 inhibitors work? (mechanism of action)
-
2:21
acc.17 highlights
-
3:29
prof marc sabatine puts odyssey outcomes and fourier in context
-
5:33
a crash course in cholesterol: pcsk9 inhibitors
-
6:50
dr. gregory schwartz on the odyssey trial - pcsk9 inhibitor vs. placebo after acs